HIV Vaccine Update

Initial results from a Phase 1 trial of the world’s first HIV vaccine has shown no adverse effects while significantly boosting immunity. The vaccine, which is called SAV001-H and is being developed by a team of scientists at Western’s Schulich School of Medicine & Dentistry in Canada, is based on a gentically modified, dead virus. If all continues to go well, the vaccine could be commercially available in five years.